<DOC>
	<DOCNO>NCT01176981</DOCNO>
	<brief_summary>The primary purpose study determine safety feasibility deliver HDMTX outpatient setting .</brief_summary>
	<brief_title>Outpatient Administration High Dose Methotrexate ( HD MTX ) Patients With Osteosarcoma</brief_title>
	<detailed_description>High Dose Methotrexate ( HDMTX ) integral part osteosarcoma therapy whose main toxicity include myelosuppression , mucositis , nephrotoxicity , hepatitis . In order deliver HDMTX therapy safely , patient require urinary alkalinization , hydration , monitor renal function , therapeutic drug monitoring , leucovorin rescue . Due require supportive care need , HDMTX historically give inpatient . In center however , HDMTX give safely outpatient order reduce health care cost , improve patient quality life deliver timely therapy limited inpatient chemotherapy bed available .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>â‰¥ 6 year age ; Localized metastatic osteosarcoma ; Adequate renal function ( GFR &gt; 70 ml/1.73m2 ) prior cycle ; No grade III/IV renal toxicity , mucositis vomit recent prior inpatient MTX cycle ; Parent and/or patient must able provide write consent , complete Patient Flow Sheets English . Patients , opinion primary healthcare team , may able comply safety monitoring requirement study , compliance likely suboptimal . Pregnant female Breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>pediatrics</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Outpatient</keyword>
</DOC>